De Novo Drug Design as GPT Language Modeling: Large Chemistry Models With Supervised and Reinforcement Learning
ISEF · 2024 Computational Biology and Bioinformatics Second Award
Overview
In recent years, generative machine learning algorithms have been successful in designing innovative drug-like molecules. SMILES is a sequence-like language used in most effective drug design models. Due to the data’s sequential structure, models such as recurrent neural networks and transformers can design pharmacological compounds with optimized efficacy. Large language models have advanced recently, but their implications on drug design have not yet been explored. Although one study successfully pre-trained a large chemistry model (LCM), its application to specific tasks in drug discovery is unknown. In this study, the drug design task is modeled as a causal language modeling problem. Thus, the procedure of reward modeling, supervised fine-tuning, and proximal policy optimization was used to transfer the LCM to drug design, similar to Open AI's ChatGPT and InstructGPT procedures. By combining the SMILES sequence with chemical descriptors, the novel efficacy evaluation model exceeded its performance compared to previous studies. After proximal policy optimization, the drug design model generated molecules with 99.2% having efficacy pIC50 > 7 towards the amyloid precursor protein, with 100% of the generated molecules being valid and novel. This demonstrated the applicability of LCMs in drug discovery, with benefits including less data consumption while fine-tuning. The applicability of LCMs to drug discovery opens the door for larger studies involving reinforcement learning with human feedback, where chemists provide feedback to LCMs and generate higher-quality molecules. LCMs’ ability to design similar molecules from datasets paves the way for more accessible, non-patented alternatives to drug molecules.
Awards (1)
- Second Award of $2,000 $2,000
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2024
GraphChem: A Soft Graph Mixture of Experts Based Adversarial Variational Spectral Graph Autoencoder for De Novo Drug Design & Other Pharmacological Objectives
ISEF · 2024
GenLSDD: A Deep Generative Approach to Ligand and Structure-Based Drug Design
ISEF · 2021
A Deep Learning Approach to de novo Drug Design: Generating Multi-Target Drugs to Inhibit Amyloid-Beta with Applications in Neurodegenerative Disorders
ISEF · 2025
A Novel Computational Generative Model That Identifies Ligands: A Potential Way to Reduce Cost & Time in Identifying Promising Drug Candidates
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair